MedTrace Logo

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

NCT03433001 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 295

Last updated 2023-12-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the real world effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients with relapsed and/or refractory multiple myeloma (RRMM), under conditions of standard medical care. In addition, an exploratory study of biomarkers will be conducted.

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG

Ixazomib

Ixazomib capsules

DRUG

Lenalidomide

Lenalidomide capsules

DRUG

Dexamethasone

Dexamethasone tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2021-06-11
Completion
2021-06-11

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433001 on ClinicalTrials.gov